Symposia: Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Combination therapy, Antibody Therapy, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, Bioinformatics, Pediatric, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunotherapy, Immunology, Lymphoid Malignancies, Computational biology, Biological Processes, Monoclonal Antibody Therapy, Technology and Procedures, Study Population, Human, Animal model, Measurable Residual Disease , Pathogenesis, Machine learning, Omics technologies
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Combination therapy, Antibody Therapy, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, Bioinformatics, Pediatric, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunotherapy, Immunology, Lymphoid Malignancies, Computational biology, Biological Processes, Monoclonal Antibody Therapy, Technology and Procedures, Study Population, Human, Animal model, Measurable Residual Disease , Pathogenesis, Machine learning, Omics technologies
Sunday, December 8, 2024: 4:30 PM-6:00 PM
Marriott Grand Ballroom 5-6
(Marriott Marquis San Diego Marina)
Moderators:
Jan Zuna, MD, PhD, CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague
and
Sarah K Tasian, MD, ARRAY(0xe31f8dc)
Disclosures:
Tasian: Kura Oncology: Research Funding; Aleta Biotherapeutics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Other: Travel support; Wugen, Inc: Membership on an entity's Board of Directors or advisory committees; Incyte Corporation: Research Funding; Amgen: Other: Travel support.
4:30 PM
4:45 PM
5:00 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH